Cargando…

Castration for Prostatic Hypertrophy

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	1899
Materias:	Clinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335582/ https://www.ncbi.nlm.nih.gov/pubmed/36391801

Ejemplares similares

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

A Case of Castration for Hypertrophied Prostate
Publicado: (1897)

Castration in Hypertrophy of the Prostate Gland: University Medical Magazine
Publicado: (1895)

Current perspectives on bone metastases in castrate-resistant prostate cancer
por: Logothetis, Christopher, et al.
Publicado: (2018)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
por: Stein, Mark, et al.
Publicado: (2012)

Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy
por: Yu, Simon Chun Ho, et al.
Publicado: (2016)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Treatment of Hypertrophy of the Prostate at the Northampton General Infirmary
Publicado: (1895)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
por: Snaterse, Gido, et al.
Publicado: (2021)

A Case of Hypertrophy of the Nymphæ
por: Hardon, Virgil O.
Publicado: (1886)

Prostatic Hypertrophy
por: Clinton, Marshall
Publicado: (1901)

Hypertrophy of the Prostate
por: McNeil, A.
Publicado: (1885)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer
por: Park, Jong-Lyul, et al.
Publicado: (2018)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
por: Lin, Hui-Ming, et al.
Publicado: (2017)

Hypertrophied Tonsils: A Clinical Lecture
por: Calhoun, A. W.
Publicado: (1885)

Hypertrophy of the Heart and Effusion within the Pericardium
por: Hard, Chester
Publicado: (1879)

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis
por: Simões, Joana, et al.
Publicado: (2018)

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
por: Meyer, Andrew, et al.
Publicado: (2012)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Liaw, Bobby C, et al.
Publicado: (2022)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
por: Bratt, O, et al.
Publicado: (2009)

Hypertrophy of the Prostate Gland
Publicado: (1891)

The Treatment of Prostatic Hypertrophy
por: Durand, C. Ferdinand
Publicado: (1898)

Prostatic Hypertrophy Treatment
por: Babler, E. A.
Publicado: (1906)

Conservation in Prostatic Hypertrophy
por: Wilson, Nelson W.
Publicado: (1910)

Hypertrophy of the Prostate in Dogs
Publicado: (1897)

Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
por: Calderoni, Letizia, et al.
Publicado: (2023)

Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer
por: Koie, Takuya, et al.
Publicado: (2020)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pf8c9i7jibojqovl55fitgg9nq